Nrf2–ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases

I Buendia, P Michalska, E Navarro, I Gameiro… - Pharmacology & …, 2016 - Elsevier
Neurodegenerative diseases (NDDs) are predicted to be the biggest health concern in this
century and the second leading cause of death by 2050. The main risk factor of these …

Pluripotent stem cells progressing to the clinic

A Trounson, ND DeWitt - Nature reviews Molecular cell biology, 2016 - nature.com
Basic experimental stem cell research has opened up the possibility of many diverse clinical
applications; however, translation to clinical trials has been restricted to only a few diseases …

When it comes to an end: oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration

P Michalska, R León - Antioxidants, 2020 - mdpi.com
Neurodegenerative diseases are characterized by a progressive loss of neurons in the brain
or spinal cord that leads to a loss of function of the affected areas. The lack of effective …

Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS

S Petri, S Körner, M Kiaei - Neurology research international, 2012 - Wiley Online Library
Nrf2 (nuclear erythroid 2‐related factor 2) is a basic region leucine‐zipper transcription
factor which binds to the antioxidant response element (ARE) and thereby regulates the …

Motoneuron loss is associated with sarcopenia

M Drey, B Krieger, CC Sieber, JM Bauer… - Journal of the American …, 2014 - Elsevier
Objectives Sarcopenia, age-related muscle wasting, is associated with increased morbidity
and mortality in the affected individuals. The pathogenesis of sarcopenia is not yet fully …

Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation

E Pena-Altamira, F Prati, F Massenzio… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: The importance of microglia in most neurodegenerative pathologies, from
Parkinson's disease to amyotrophic lateral sclerosis and Alzheimer's disease, is increasingly …

Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning

V Kumar, A Islam, MI Hassan, F Ahmad - European Journal of Medicinal …, 2016 - Elsevier
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with
motor neuron degeneration, muscle weakness, paralysis and finally death. The proposed …

Current therapy of drugs in amyotrophic lateral sclerosis

H Lu, WD Le, YY Xie, XP Wang - Current neuropharmacology, 2016 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS), commonly termed as motor neuron disease (MND) in
UK, is a chronically lethal disorder among the neurodegenerative diseases, meanwhile. ALS …

[HTML][HTML] Plant-derived natural compounds for the treatment of amyotrophic lateral sclerosis: an update

RH Mir, AJ Shah, S Sabreen, TU Wani… - Current …, 2022 - ncbi.nlm.nih.gov
Background Amyotrophic lateral sclerosis (ALS) is a motor neuron disease (MND) that
typically causes death within 3-5 years after diagnosis. Regardless of the substantial …

Simple biological systems for assessing the activity of superoxide dismutase mimics

A Tovmasyan, JS Reboucas, L Benov - Antioxidants & Redox …, 2014 - liebertpub.com
Significance: Half a century of research provided unambiguous proof that superoxide and
species derived from it—reactive oxygen species (ROS)—play a central role in many …